ArticleJournal of cardiothoracic surgery2026
Construction of PANoptosis-related lncRNA prognostic model and immunotherapy sensitivity analysis in lung adenocarcinoma.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundLung cancer is the cancer with the highest mortality rate worldwide. PANoptosis is characterized by inflammatory lytic cell death facilitated by caspases and RIPKs. We determined the construction of PANoptosis-related lncRNA, constructed a prognosis-related model, and further screened potential therapeutic drugs.
methodsThe TCGA database was used to obtain the RNA-seq-based transcriptome profiling data, clinical information, and mutation data. We used multivariable Cox regression analysis to obtain PANoptosis-related lncRNAs. We then used the training group to build the prognostic model and used the testing group to verify the accuracy of the model. Calibration curves showed the difference between the predicted and observed outcomes. PCA analysis was used to explore the distribution of LUAD patients with high- and low-risk groups. The GO and GSEA enrichment analyses were performed. Immune cell infiltration and TMB analysis were performed using CIBERSORT and maftools algorithm. The TIDE algorithm was used to predict immunotherapy sensitivity and further predicted anti-tumor immune drugs. qPCR was used for experimental verification.
resultsWe identified 163 PANoptosis-related lncRNAs and identified 6 lncRNAs as independent prognostic factors. The PFS and OS of the low-risk group were significantly higher than those of the high-risk group. The risk signature is a prognostic factor, independent of other factors. Different stages (stages I-II and III-IV) could well predict the survival rate of LUAD patients and these lncRNAs can reliably stratify patient prognosis. GSEA analysis showed that chromosome segregation and activation of immune response were significantly enriched in the high- and low-risk groups. The high-risk group showed a lower fraction of T cells CD4 memory resting and a higher proportion of NK cells resting. The OS of the low TMB group was significantly lower than the high TMB group. Furthermore, the drug sensitivity of the high-risk group is significantly higher than the low-risk group. And the high-risk lncRNAs may serve as therapeutic targets.
conclusionsIn summary, the 6 PANoptosis-related lncRNAs can well predict the prognosis of LUAD patients, which may provide new insight for survival prediction and clinical immunotherapy of LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.